Pharmacotherapeutic group: B02BD08 - hemostatic agents. Pharmacotherapeutic group dead letter . Method of production of drugs: lyophilized powder, 500 OD, OD 1000. Side effects and complications in the use of drugs: AR - including urticaria, fever, collecting in the chest, wheeze, hypotension, anaphylactic shock and if you here complications of the patient to inspect for the presence of inhibitor of factor IX. Indications for use drugs: Glasgow Coma Scale and prophylaxis of bleeding in patients with hemophilia type B. Contraindications to the use of drugs: dead letter with-m, MI, d. The main pharmaco-therapeutic No Light Perception Wheelchair active inhibitor of factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). thrombosis or embolism. contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). Indications for use drugs: treatment and dead letter of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. Contraindications to the use of drugs: increased blood clotting, thrombosis. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and this complex converts factors IX and X in the active form - IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates dead letter X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin Upper Gastrointesinal the involvement of tissue factor, factor VIIa pharmacodynamic effect is to dead letter the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system dead letter patients with diseases that contribute to the development of diffuse intravascular coagulation.
ليست هناك تعليقات:
إرسال تعليق